About ABBV-744 in clinical trials for non-small cell lung cancer (NSCLC)
In Phase C, participants will acquire ABBV-744 and oral navitoclax. In Segment D, individuals will acquire ABBV-744 and ruxolitinib. Participants will get treatment right until disorder progression or even the contributors are unable to tolerate the study drugs.Overall, our present work highlights the potential utilization of ARV-825 in combination